BCL9L

Summary

BCL9L (BCL9 like, HGNC:23688) is a protein-coding gene on chromosome 11q23.3, encoding B-cell CLL/lymphoma 9-like protein (Q86UU0). Transcriptional regulator that acts as an activator.

Enables beta-catenin binding activity. Involved in several processes, including negative regulation of transforming growth factor beta receptor signaling pathway; positive regulation of epithelial to mesenchymal transition; and positive regulation of transcription by RNA polymerase II. Located in fibrillar center and nucleoplasm. Part of beta-catenin-TCF complex.

Source: NCBI Gene 283149 — RefSeq curated summary.

At a glance

• Gene–disease (curated): visceral heterotaxy (Moderate, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 314 total
• Druggable target: yes
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 2 cancer types
• MANE Select transcript: NM_001378213

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23688
Approved symbol	BCL9L
Name	BCL9 like
Location	11q23.3
Locus type	gene with protein product
Status	Approved
Aliases	DLNB11, B9L, Bcl9-2
Ensembl gene	ENSG00000186174
Ensembl biotype	protein_coding
OMIM	609004
Entrez	283149

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000334801, ENST00000526143, ENST00000527266, ENST00000530293, ENST00000683865, ENST00000913860

RefSeq mRNA: 3 — MANE Select: NM_001378213 NM_001378213, NM_001378214, NM_182557

CCDS: CCDS8403, CCDS91603

Canonical transcript exons

ENST00000683865 — 10 exons

Exon	Start	End
ENSE00002156493	118918826	118918879
ENSE00002175100	118909914	118910015
ENSE00003473850	118907483	118907602
ENSE00003540038	118902990	118903074
ENSE00003640614	118908270	118908655
ENSE00003722859	118899917	118900198
ENSE00003726698	118900619	118902908
ENSE00003742385	118903236	118903452
ENSE00003752118	118925238	118925926
ENSE00003922236	118896136	118899508

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 95.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.4848 / max 252.2367, expressed in 1787 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122650	24.0772	1773
122638	1.8165	917
122629	1.0341	499
122651	0.8468	477
206470	0.8365	427
122631	0.5956	314
122632	0.5856	299
122630	0.5769	306
122639	0.3961	169
122635	0.3616	178

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	95.57	gold quality
right coronary artery	UBERON:0001625	95.45	gold quality
stromal cell of endometrium	CL:0002255	94.59	gold quality
right uterine tube	UBERON:0001302	94.21	gold quality
mucosa of stomach	UBERON:0001199	93.77	gold quality
popliteal artery	UBERON:0002250	93.57	gold quality
tibial artery	UBERON:0007610	93.55	gold quality
ileal mucosa	UBERON:0000331	93.35	gold quality
right ovary	UBERON:0002118	93.03	gold quality
nipple	UBERON:0002030	93.01	gold quality
cortical plate	UBERON:0005343	93.00	gold quality
aorta	UBERON:0000947	92.91	gold quality
kidney epithelium	UBERON:0004819	92.85	silver quality
descending thoracic aorta	UBERON:0002345	92.78	gold quality
body of uterus	UBERON:0009853	92.77	gold quality
gingival epithelium	UBERON:0001949	92.71	gold quality
vermiform appendix	UBERON:0001154	92.53	gold quality
left uterine tube	UBERON:0001303	92.49	gold quality
left adrenal gland cortex	UBERON:0035825	92.26	gold quality
thoracic aorta	UBERON:0001515	92.25	gold quality
coronary artery	UBERON:0001621	92.23	gold quality
gall bladder	UBERON:0002110	92.19	gold quality
ectocervix	UBERON:0012249	92.19	gold quality
ascending aorta	UBERON:0001496	92.18	gold quality
left adrenal gland	UBERON:0001234	92.16	gold quality
left coronary artery	UBERON:0001626	92.10	gold quality
left ovary	UBERON:0002119	91.98	gold quality
adrenal cortex	UBERON:0001235	91.88	gold quality
germinal epithelium of ovary	UBERON:0001304	91.69	gold quality
left ventricle myocardium	UBERON:0006566	91.57	silver quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-9543	yes	14.58
E-ANND-3	no	3.73

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2, PAX6

miRNA regulators (miRDB)

129 targeting BCL9L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-548D-3P	99.87	70.67	4362

Literature-anchored findings (GeneRIF, showing 13)

• crystallographic analysis of how beta-catenin, BCL9, BCL9-2 and Tcf4 interact (PMID:17052462)
• Pygo2 PHD is the only known PHD finger that is capable of interacting simultaneously with two functional ligands, B9L and BCL9. (PMID:20637214)
• BCL9-2 promotes early phases of intestinal tumor progression in humans and in transgenic mice. BCL9-2 increases the expression of a subset of canonical Wnt target genes but also regulates genes that are required for early stages of tumor progression. (PMID:21703997)
• Data show that beta-catenin/BCL9-Like (BCL9L)/T-cell factor 4 (TCF4) signalling directly targets the GCM1/syncytin pathway and thereby regulates the fusion of human choriocarcinoma cells. (PMID:22109522)
• BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells. (PMID:25149534)
• The inhibition of the transcriptional activity of BCL9-2 by WWOX and HDAC3 constitutes a new molecular mechanism and provides new insight for a broad range of cancers. (PMID:25678599)
• we identify BCL9L as a novel regulator of TGF-beta-induced EMT in pancreatic cancer. (PMID:27713160)
• BCL9L dysfunction contributes to aneuploidy tolerance in both TP53-WT and mutant cells by reducing basal caspase-2 levels and preventing cleavage of MDM2 and BID. (PMID:28073006)
• Dual-luciferase reporter confirmed that BCL9L is the target gene of both miR-22 and miR-214. (PMID:30698996)
• BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. (PMID:33767438)
• Type I collagen promotes tumor progression of integrin beta1 positive gastric cancer through a BCL9L/beta-catenin signaling pathway. (PMID:34319913)
• The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis. (PMID:34545187)
• Wnt/beta-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. (PMID:35628130)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	bcl9l	ENSDARG00000055054
mus_musculus	Bcl9l	ENSMUSG00000063382
rattus_norvegicus	Bcl9l	ENSRNOG00000012420

Paralogs (1): BCL9 (ENSG00000116128)

Protein

Protein identifiers

B-cell CLL/lymphoma 9-like protein — Q86UU0 (reviewed: Q86UU0)

Alternative names: Protein BCL9-2

All UniProt accessions (2): A0A087WZX0, Q86UU0

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1.

Subunit / interactions. Found in a complex with CDC73; CTNNB1 and PYGO1. Interacts with CTNNB1.

Subcellular location. Nucleus.

Tissue specificity. Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.

Domain organisation. Tne C-terminal domain is important for its transactivation activity.

Similarity. Belongs to the BCL9 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q86UU0-1	1	yes
Q86UU0-2	2
Q86UU0-3	3
Q86UU0-4	4

RefSeq proteins (3): NP_001365142, NP_001365143, NP_872363 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR015668	Bcl-9/Bcl-9l	Family
IPR024670	BCL9_beta-catenin-bd_dom	Domain

Pfam: PF11502

UniProt features (60 total): modified residue 26, compositionally biased region 19, region of interest 5, splice variant 4, strand 2, helix 2, chain 1, cross-link 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4UP0	X-RAY DIFFRACTION	1.28
4UP5	X-RAY DIFFRACTION	1.65
2XB1	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UU0-F1	42.86	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (27): 21, 25, 36, 88, 108, 110, 116, 118, 137, 424, 514, 680, 750, 813, 915, 926, 938, 942, 947, 975 …

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex
R-HSA-3769402	Deactivation of the beta-catenin transactivating complex
R-HSA-162582	Signal Transduction
R-HSA-195721	Signaling by WNT
R-HSA-201681	TCF dependent signaling in response to WNT

MSigDB gene sets: 217 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, FXR_IR1_Q6, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_SOMATIC_STEM_CELL_POPULATION_MAINTENANCE, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, CMYB_01, AAGCCAT_MIR135A_MIR135B, AREB6_01, MEF2_02, USF_C, CAGCTG_AP4_Q5, SP1_Q2_01

GO Biological Process (10): transcription by RNA polymerase II (GO:0006366), positive regulation of epithelial to mesenchymal transition (GO:0010718), regulation of cell morphogenesis (GO:0022604), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), somatic stem cell population maintenance (GO:0035019), skeletal muscle cell differentiation (GO:0035914), myoblast differentiation (GO:0045445), positive regulation of transcription by RNA polymerase II (GO:0045944), canonical Wnt signaling pathway (GO:0060070), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (2): transcription coactivator activity (GO:0003713), beta-catenin binding (GO:0008013)

GO Cellular Component (4): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleoplasm (GO:0005654), beta-catenin-TCF complex (GO:1990907)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
TCF dependent signaling in response to WNT	2
Signal Transduction	1
Signaling by WNT	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
cell differentiation	2
positive regulation of DNA-templated transcription	2
cellular anatomical structure	2
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
positive regulation of cell differentiation	1
positive regulation of multicellular organismal process	1
cell morphogenesis	1
regulation of anatomical structure morphogenesis	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
stem cell population maintenance	1
skeletal muscle tissue development	1
muscle structure development	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
Wnt signaling pathway	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
transcription coregulator activity	1
protein binding	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

772 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BCL9L	CTNNB1	P35222	908
BCL9L	HNF4A	P41235	896
BCL9L	PYGO2	Q9BRQ0	854
BCL9L	PYGO1	Q9Y3Y4	798
BCL9L	LEF1	Q9UJU2	593
BCL9L	TNKS2	Q9H2K2	560
BCL9L	BCL9	O00512	556
BCL9L	TNKS	O95271	538
BCL9L	CSNK1A1	P48729	533
BCL9L	CEP250	Q9BV73	455
BCL9L	WNT16	Q9UBV4	451
BCL9L	SOD3	P08294	440
BCL9L	AXIN1	O15169	436
BCL9L	CROCC	Q5TZA2	424
BCL9L	AXIN2	Q9Y2T1	422

IntAct

45 interactions, top by confidence:

A	B	Type	Score
PYGO1	BCL9	psi-mi:“MI:0914”(association)	0.700
PYGO2	BCL9	psi-mi:“MI:0914”(association)	0.690
HSPA2	DNAJC13	psi-mi:“MI:0914”(association)	0.530
BCL9L	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
Ctnnb1	BCL9L	psi-mi:“MI:0915”(physical association)	0.370
BCL9L	WWOX	psi-mi:“MI:0915”(physical association)	0.370
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
BCL9L	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
HSPA8	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
AR	MED6	psi-mi:“MI:2364”(proximity)	0.270
RAVER1	KDM6A	psi-mi:“MI:2364”(proximity)	0.270
LHX2	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
LHX4	BCL9	psi-mi:“MI:2364”(proximity)	0.270
LHX6	BCL9	psi-mi:“MI:2364”(proximity)	0.270
PAX9	BCL9	psi-mi:“MI:2364”(proximity)	0.270
SOX2	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SP7	IGF2BP3	psi-mi:“MI:2364”(proximity)	0.270
TBR1	BCL9	psi-mi:“MI:2364”(proximity)	0.270
TLX3	BCL9	psi-mi:“MI:2364”(proximity)	0.270
BRAF	BCL9L	psi-mi:“MI:2364”(proximity)	0.270
FBXW7	BCL9L	psi-mi:“MI:2364”(proximity)	0.270
SMAD4	BCL9L	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (62): CTNNB1 (Affinity Capture-Western), BCL9L (Proximity Label-MS), BCL9L (Biochemical Activity), BCL9L (Affinity Capture-MS), BCL9L (Affinity Capture-MS), BCL9L (Affinity Capture-MS), BCL9L (Affinity Capture-RNA), BCL9L (Affinity Capture-MS), BCL9L (Affinity Capture-MS), BCL9L (Affinity Capture-MS), BCL9 (Affinity Capture-MS), BCL9L (Affinity Capture-MS), SSBP3 (Affinity Capture-MS), BCL9L (Affinity Capture-MS), PYGO2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IBL7, A3RK74, A4L7N3, A5D7F6, B2RWS6, B5DE09, E1BPQ1, G3V7R4, O00512, O43524, P11420, P45481, P78364, Q09472, Q12778, Q13227, Q14686, Q15596, Q17BA4, Q61026, Q64028, Q66JJ0, Q67FY2, Q6AI39, Q6JHU9, Q6T264, Q7ZUK7, Q810W5, Q86UU0, Q8CHH5, Q8CHP6, Q8IXK0, Q8IZL2, Q921N8, Q924H2, Q92585, Q92793, Q961D9, Q96JK9, Q96RN5

Diamond homologs: O00512, Q67FY2, Q67FY3, Q86UU0, Q95KQ6, Q9D219

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 40 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Deactivation of the beta-catenin transactivating complex	5	38.8×	6e-05

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	5	40.4×	5e-05
somatic stem cell population maintenance	5	34.4×	8e-05
osteoblast differentiation	6	20.2×	8e-05
neuron differentiation	5	13.9×	2e-03
chromatin remodeling	5	10.1×	5e-03
positive regulation of gene expression	6	6.5×	8e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 2 cancer types — COAD, COADREAD.

Clinical variants and AI predictions

ClinVar

314 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	276
Likely benign	8
Benign	14

Top pathogenic / likely-pathogenic (0)

SpliceAI

1623 predictions. Top by Δscore:

Variant	Effect	Δscore
11:118899911:TCGCA:T	donor_loss	1.0000
11:118899912:CGCA:C	donor_loss	1.0000
11:118899913:GCACC:G	donor_loss	1.0000
11:118899914:CA:C	donor_loss	1.0000
11:118899915:AC:A	donor_loss	1.0000
11:118899916:C:CT	donor_loss	1.0000
11:118902984:GCTCA:G	donor_loss	1.0000
11:118902985:CTCA:C	donor_loss	1.0000
11:118902986:TCAC:T	donor_loss	1.0000
11:118902988:A:T	donor_loss	1.0000
11:118902989:C:A	donor_loss	1.0000
11:118903234:A:AC	donor_gain	1.0000
11:118903235:C:CC	donor_gain	1.0000
11:118907479:TCACT:T	donor_loss	1.0000
11:118907480:CACTG:C	donor_loss	1.0000
11:118907481:A:AC	donor_gain	1.0000
11:118907481:A:T	donor_loss	1.0000
11:118907482:C:CA	donor_gain	1.0000
11:118907482:CT:C	donor_gain	1.0000
11:118907598:CACCT:C	acceptor_gain	1.0000
11:118907599:ACCT:A	acceptor_gain	1.0000
11:118907600:CCTC:C	acceptor_gain	1.0000
11:118907601:CT:C	acceptor_gain	1.0000
11:118907603:C:CC	acceptor_gain	1.0000
11:118907608:C:CT	acceptor_gain	1.0000
11:118907608:C:T	acceptor_gain	1.0000
11:118907609:A:T	acceptor_gain	1.0000
11:118907612:C:CT	acceptor_gain	1.0000
11:118907613:A:T	acceptor_gain	1.0000
11:118899506:TCC:T	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000049744 (11:118920252 A>G), RS1000198472 (11:118897469 T>A,G), RS1000223467 (11:118902818 G>C), RS1000374835 (11:118902500 G>A,C,T), RS1000398096 (11:118908152 T>C), RS1000506419 (11:118917513 C>T), RS1000594167 (11:118924807 G>C), RS1000607410 (11:118911250 G>C), RS1000670131 (11:118897736 G>A,C,T), RS1000771263 (11:118896143 T>C,G), RS1000825429 (11:118899875 C>T), RS1000914117 (11:118912475 T>C), RS1000993255 (11:118911516 A>G), RS1001023248 (11:118918476 G>A), RS1001023461 (11:118925272 G>A)

Disease associations

OMIM: gene MIM:609004 | disease phenotypes: MIM:615378

GenCC curated gene-disease

Disease	Classification	Inheritance
visceral heterotaxy	Moderate	Autosomal recessive

Mondo (2): atrial fibrillation, familial, 14 (MONDO:0014156), visceral heterotaxy (MONDO:0018677)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009597_76	Multiple sclerosis	9.000000e-11
GCST009798_24	Asthma	4.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5291978 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.28	Ki	5200	nM	CHEMBL5274911

PubChem BioAssay actives

1 with measured affinity, of 1 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[3-cyclohexyl-4-[(3R)-pyrrolidin-3-yl]oxyphenyl]-[4-(3-fluoro-5-piperazin-1-ylbenzoyl)piperazin-1-yl]methanone	1924310: Binding affinity to beta catenin (unknown origin) to BCL assessed as inhibition constant by alpha screening assay	ki	5.2000	uM

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases abundance, increases expression, affects cotreatment	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects response to substance, increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	increases abundance, affects methylation, affects cotreatment, decreases expression	2
Valproic Acid	affects expression, increases methylation	2
aristolochic acid I	decreases expression, increases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	decreases expression	1
bufotalin	increases expression	1
triphenyl phosphate	affects expression	1
lead acetate	increases expression	1
titanium dioxide	decreases methylation	1
decabromobiphenyl ether	decreases expression	1
afimoxifene	decreases expression, decreases reaction	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
coumarin	decreases phosphorylation	1
pentanal	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
mono(carboxy-isooctyl)phthalate	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5227394	Binding	Binding affinity to beta catenin (unknown origin) to BCL assessed as inhibition constant by alpha screening assay	Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9A2	Ubigene HEK293 BCL9L KO	Transformed cell line	Female

Clinical trials (associated diseases)

3 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01591928	Not specified	COMPLETED	Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study
NCT01929967	Not specified	COMPLETED	Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data
NCT02432079	Not specified	RECRUITING	Molecular Genetics of Heterotaxy and Related Congenital Heart Defects